Diametric Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Diametric Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-8,589	Closed	-$964K	–	214
2020 Q2	$964K	Buy	+8,589	New	+$912K	0.74%	53
2019 Q3	–	Sell	-25,651	Closed	-$3.36M	–	154
2019 Q2	$3.36M	Buy	+25,651	New	+$3.31M	2.13%	11
2018 Q3	–	Sell	-11,669	Closed	-$1.45M	–	130
2018 Q2	$1.45M	Sell	11,669 -1,735	-13%	-$203K	1.36%	34
2018 Q1	$1.49M	Sell	13,404 -2,341	-15%	-$280K	1.13%	35
2017 Q4	$1.88M	Buy	+15,745	New	+$1.92M	1.14%	37

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Diametric Capital's ALXN Position: Q3 2020 in Review

Diametric Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 8,589 shares — an estimated $964K sold.

Diametric Capital first reported a position in ALXN in Q4 2017 and held it in 5 quarters. The position peaked at $3.36M in Q2 2019. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

Diametric Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Diametric Capital sold 8,589 Alexion Pharmaceuticals shares in Q3 2020, an estimated $964K.
Diametric Capital first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 5 quarters.
Diametric Capital's Alexion Pharmaceuticals position peaked at $3.36M in Q2 2019.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Diametric Capital's 13F filing for Q3 2020, filed 13 Nov 2020.